Sequella, Inc. Receives NIH Grant to Develop Tuberculosis Diagnostic Device

Apr 23, 2001, 01:00 ET from Sequella, Inc.

    ROCKVILLE, Md., April 23 /PRNewswire Interactive News Release/ --
 Sequella, Inc. today announced it received a Small Business Innovative
 Research (SBIR) Grant from the National Institute of Allergy and Infectious
 Diseases (NIAID) that will drive development of an important new diagnostic
 device for tuberculosis (TB).  This device has the potential to specifically
 diagnose the disease and evaluate drug resistance of TB organisms within two
 days, which would represent a major improvement over existing TB diagnostic
 tools.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20010117/DCW007LOGO-b )
     TB is the leading single-agent infectious disease killer in the world,
 claiming more than 2 million lives each year.  A key reason for the staggering
 morbidity and mortality of this disease is the evolution of bacteria resistant
 to one or all of the front-line anti-tubercular drugs.
     The delayed recognition of drug resistance is one of the biggest
 challenges in the control of drug-resistant TB.  Diagnostic methods of
 evaluating infection and drug resistance often require three to six weeks
 before a result is obtained, even using the most state-of-the-art methods.
 The length of time required for these tests results in inappropriate therapy
 of infected patients, producing increasingly drug resistant bacteria and a
 dramatically reduced likelihood of cure.
     The TB diagnostic device under development by Sequella has the potential
 to positively identify drug resistance of TB organisms within 48 hours.  This
 innovative device incorporates a virus that emits light in the presence of
 live Mycobacterium tuberculosis.  This light can be detected with a piece of
 film or a digital camera, providing physicians with a rapid and inexpensive
 method for the identification of TB and determination of TB drug
 susceptibility.
     Dr. William Jacobs at the Albert Einstein College of Medicine originally
 developed the concept for and validated the theory behind the device, which he
 calls "the Bronx Box."  As part of its aggressive program to develop the most
 promising technologies to combat TB, Sequella has licensed the Bronx Box
 concept for commercial development.
     Dr. Carol Nacy, CEO of Sequella, Inc., commented, "This technology is
 wonderfully innovative and promising, and we are pleased with the confidence
 that NIAID has in our ability to commercialize this product.  The SBIR will
 allow us to field a new device that could greatly reduce the global burden of
 drug-resistant TB."
     Sequella, Inc., http://www.sequella.com , is a development stage
 biotechnology company formed in 1997 to develop and market new products for
 the treatment of global infectious diseases that impact the public health.
 The company, headquartered in Rockville, MD, is focusing its initial research
 efforts on therapeutics, vaccines and diagnostics to address the growing TB
 problem worldwide.
     Some of the matters discussed in this press release are forward-looking
 and therefore subject to risks and uncertainties that could cause actual
 results to differ from those stated or implied in this report.  These risks
 and uncertainties include but are not limited to those relating to new product
 development, results of future clinical trials, and availability of sources of
 capital, as well as risks discussed in Sequella's Business Plan and Private
 Placement documents.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X46495366
 
 

SOURCE Sequella, Inc.
    ROCKVILLE, Md., April 23 /PRNewswire Interactive News Release/ --
 Sequella, Inc. today announced it received a Small Business Innovative
 Research (SBIR) Grant from the National Institute of Allergy and Infectious
 Diseases (NIAID) that will drive development of an important new diagnostic
 device for tuberculosis (TB).  This device has the potential to specifically
 diagnose the disease and evaluate drug resistance of TB organisms within two
 days, which would represent a major improvement over existing TB diagnostic
 tools.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20010117/DCW007LOGO-b )
     TB is the leading single-agent infectious disease killer in the world,
 claiming more than 2 million lives each year.  A key reason for the staggering
 morbidity and mortality of this disease is the evolution of bacteria resistant
 to one or all of the front-line anti-tubercular drugs.
     The delayed recognition of drug resistance is one of the biggest
 challenges in the control of drug-resistant TB.  Diagnostic methods of
 evaluating infection and drug resistance often require three to six weeks
 before a result is obtained, even using the most state-of-the-art methods.
 The length of time required for these tests results in inappropriate therapy
 of infected patients, producing increasingly drug resistant bacteria and a
 dramatically reduced likelihood of cure.
     The TB diagnostic device under development by Sequella has the potential
 to positively identify drug resistance of TB organisms within 48 hours.  This
 innovative device incorporates a virus that emits light in the presence of
 live Mycobacterium tuberculosis.  This light can be detected with a piece of
 film or a digital camera, providing physicians with a rapid and inexpensive
 method for the identification of TB and determination of TB drug
 susceptibility.
     Dr. William Jacobs at the Albert Einstein College of Medicine originally
 developed the concept for and validated the theory behind the device, which he
 calls "the Bronx Box."  As part of its aggressive program to develop the most
 promising technologies to combat TB, Sequella has licensed the Bronx Box
 concept for commercial development.
     Dr. Carol Nacy, CEO of Sequella, Inc., commented, "This technology is
 wonderfully innovative and promising, and we are pleased with the confidence
 that NIAID has in our ability to commercialize this product.  The SBIR will
 allow us to field a new device that could greatly reduce the global burden of
 drug-resistant TB."
     Sequella, Inc., http://www.sequella.com , is a development stage
 biotechnology company formed in 1997 to develop and market new products for
 the treatment of global infectious diseases that impact the public health.
 The company, headquartered in Rockville, MD, is focusing its initial research
 efforts on therapeutics, vaccines and diagnostics to address the growing TB
 problem worldwide.
     Some of the matters discussed in this press release are forward-looking
 and therefore subject to risks and uncertainties that could cause actual
 results to differ from those stated or implied in this report.  These risks
 and uncertainties include but are not limited to those relating to new product
 development, results of future clinical trials, and availability of sources of
 capital, as well as risks discussed in Sequella's Business Plan and Private
 Placement documents.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X46495366
 
 SOURCE  Sequella, Inc.